With the new funding, Precipoint plans to expand internationally and enter the US market. Additionally, the Freising-based company aims to advance further technological development.
Precipoint develops digitalization solutions in the field of microscopy and, according to its own statements, is represented with its devices in many laboratories worldwide. Applications are found in medicine, research, and education. Using the company’s products, samples can be examined without expensive and time-consuming preprocessing.
Precipoint: “Prerequisites have been created to scale the company rapidly”
This year, Precipoint presented the iO:M8 ROSE solution. This enables digital examinations during ongoing cancer surgeries. Pathologists can thus determine during the procedure whether sufficient material has been removed from the patient’s body and whether the margins of the operated area are free of cancer cells. To date, such examinations are performed on-site using conventional light microscopes. Precipoint’s digital solution is intended to improve patient care and enable significant cost savings.
Stefan Jahn, Senior Investment Manager at Bm|t, says:
“Since our seed investment in 2019, the team around co-founders and managing directors Nicolas Weiß and Dominik Gerber has made tremendous progress. Renowned distribution partners have been won over, new products developed quickly and successfully launched on the market. At the same time, the prerequisites have been created to scale the company rapidly. We firmly believe that Precipoint, as an ISO 13485 certified medical device company, can successfully position its product portfolio on the European and American markets.”
